Eevia Health's Board of Directors has resolved a directed share issue of 2,700,107 shares

The Company has resolved a Directed Share Issue to a limited number of professional investors and several existing shareholders. The Board based the Directed Share Issue on the Terms of the Rights Issue communicated in June. A total of 10 guarantors have agreed to subscribe for shares in the Directed Share Issue as a means of payment for the subscription guarantee for the Rights Issue concluded in June/July 2024.

The subscription price was 0,05 euros (equal to SEK 0,57 at today's exchange rate), as stated in the Terms of the Rights issue communicated in a press release on June 5, 2024. The shares were issued for 16% of the commitment amount. This was the agreed commission when the guarantors chose to be paid in new shares. The Board of Directors of Eevia Health considers the fees to be in line with market practice.

The Directed Share Issue increases the total number of shares from 64,355,488 to 67,055,955. For existing shareholders, the Directed Share Issue will result in a dilution of approximately 4,0 percent. The weighty reason for deviation from the shareholders' pre-emptive rights for the Directed Share Issue is to improve the Company's financial position by retaining more cash from the rights issue. The Board thinks the Directed issue will benefit the Company and all its shareholders.

Advisors

Partner Fondkommission is the financial advisor and issuing agent in Sweden. OP Bank is the issuing agent in Finland.

For more information, please contact: 

Stein Ulve, CEO  Joel Westerström, Partner Fondkommission

[email protected]  Email: [email protected]

Telephone: +358 400 22 5967  Telephone: +46 735 11 68 53

This information is such that Eevia Health Plc is required to make it public in accordance with the EU's Market Abuse Regulation (MAR). The information was made public by the Company's contact person above on September 19, 2024, at 08:30 CEST.

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally, and these global brands utilize the ingredients in their consumer product formulas.

Eevia Health manufactures 100% organically certified plant extracts. Our commitment to sustainable and organic manufacturing practices, such as wild harvesting our raw materials and operating a modern green chemistry production facility, ensures the highest quality products for our customers.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. In June 2021, Eevia listed its shares on the Spotlight Stock Market in Sweden under the short name EEVIA (https://spotlightstockmarket.com/en/companies/irabout?InstrumentId=XSAT000085FD).

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE IN CONFLICT WITH APPLICABLE RULES OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS.

IMPORTANT INFORMATION ABOUT THE PRESS RELEASE AND DOCUMENTS

This press release does not constitute an offer to acquire, subscribe to, or otherwise trade in shares, subscription rights, paid subscription shares, or other securities in Eevia Health Plc. Investors must subscribe to or acquire securities based on the IM information. No action has been taken, and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.

This press release must not be published or distributed, directly or indirectly, to or within Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland, the US, or any other jurisdiction where the distribution of this press release is against the law. Similarly, this press release does not constitute an offer to sell new shares, paid subscription shares, subscription rights, or other securities to anyone in a jurisdiction where it is not allowed to make such an offer to such a person or where such action would require an additional prospectus, registration, or measures other than those required under Swedish law. The IM, registration slip, and other documents attributable to the Rights Issue may not be distributed to or within any country where such distribution or Rights Issue requires measures as stated in the preceding sentence or where this would contravene the law of that country.

No shares, subscription rights, paid subscription shares, or other securities have been registered or will be registered under the 1933 United States Securities Act in its current version ("the Securities Act") or securities legislation in any state or other jurisdiction of the US, and may not be offered, subscribed to, utilized, pledged, sold, resold, granted, supplied, or otherwise transferred, directly or indirectly, to or within the US, except in accordance with any applicable exemption from or by a transaction that is not covered by the registration requirements of the Securities Act and in accordance with the securities legislation in the relevant state or other jurisdiction of the US.